CAJ | 학술논문

目的：探讨奥美沙坦酯联合苯磺酸氨氯地平对维持性血液透析（ MHD）高血压患者血压和微炎症状态的影响。方法80例MHD高血压患者应用随机数字表法随机分为对照组和治疗组（每组40例），对照组患者给予苯磺酸氨氯地平口服，治疗组患者给予奥美沙坦酯联合苯磺酸氨氯地平口服，疗程均为8周。观察2组治疗前后血压及高敏C反应蛋白（ hs-CRP）、α1-酸性糖蛋白（α1-AAG）水平变化。同时设40例健康对照组。结果治疗组总有效率为90．5％，明显高于对照组的67．5％（P＜0．05），2组治疗后收缩压和舒张压均较治疗前明显下降（P＜0．05），但治疗组降压幅度更显著（P＜0．05）；对照组hs-CRP、α1-AAG水平明显高于健康者（P＜0．05），治疗组在给予奥美沙坦酯治疗后hs-CRP、α1-AAG水平较对照组明显下降，差异有统计学意义（P＜0．05）。结论奥美沙坦酯联合苯磺酸氨氯地平可以显著降低MHD高血压患者的血压，并可改善MHD患者的微炎症状态，值得推广。
목적：탐토오미사탄지연합분광산안록지평대유지성혈액투석（ MHD）고혈압환자혈압화미염증상태적영향。방법80례MHD고혈압환자응용수궤수자표법수궤분위대조조화치료조（매조40례），대조조환자급여분광산안록지평구복，치료조환자급여오미사탄지연합분광산안록지평구복，료정균위8주。관찰2조치료전후혈압급고민C반응단백（ hs-CRP）、α1-산성당단백（α1-AAG）수평변화。동시설40례건강대조조。결과치료조총유효솔위90．5％，명현고우대조조적67．5％（P＜0．05），2조치료후수축압화서장압균교치료전명현하강（P＜0．05），단치료조강압폭도경현저（P＜0．05）；대조조hs-CRP、α1-AAG수평명현고우건강자（P＜0．05），치료조재급여오미사탄지치료후hs-CRP、α1-AAG수평교대조조명현하강，차이유통계학의의（P＜0．05）。결론오미사탄지연합분광산안록지평가이현저강저MHD고혈압환자적혈압，병가개선MHD환자적미염증상태，치득추엄。
Objective To investigate the efficacy of benzene sulfonic acid amlodipine combined with Olmesartan medoxomil on blood pressure and micro -inflammation state in maintenance hemodialysis patients with hypertension . Methods 80 maintenance hemodialysis patients with hypertension were randomly divided into control group and treat -ment group using random number table ( n=40 each ) .The contuol group received oral benzene sulfonic acid amlodip-ine, while treatment group was given oral benzene sulfonic acid amlodipine combined with olmesartan medoxomil .The course of treatment in the two groups was 8 weeks.The changes of blood pressure , high-sensitivity C-reactive protein ( hs-CRP) and α1-acid glycoprotein (α1-AAG) were observed before and after treatment between the two groups . In addition , 40 normal individuals as the healthy control subjects .Results The total effective rate of treatment groups was 90.5%, which was higher than 67.5%of control groups (P<0.05).After treatment, both systolic blood pressure and diastolic blood preassure in the two groups was significantly decreased than before treatment (P<0.05), while the decompression range of blood pressure in the treatment group was significantly greater than that in the control group ( P<0.05);compared with healthy people , hs-CRP and α1-AAG were elevated significantly with maintenance hemodialy-sis patients (P<0.05).The level of hs-CRP and α1-AAG were decreased in maintenance hemodialysis patient with taking Olmesartan medoxomil in treatment group .Conclusion Olmesartan medoxomil combined with Benzene Sulfonic Acid Amlodipine can obviously decrease the blood pressure in the maintenance hemodialysis patients with hypenension , and relieve the micro-inflammation state in maintenance hemodialysis patients , is worth promoting the application .